Cardio Diagnostics Holdings (NASDAQ: CDIO) took the spotlight in the latest episode of The BioMedWire Podcast, featuring CEO and Co-Founder Dr. Meesha Dogan discussing the company’s mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics and artificial intelligence. During the interview, Dogan highlighted Cardio Diagnostics’ expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as the company’s progress through the Medicare reimbursement process, noting that CPT coding and payment steps have been completed while coverage determination remains underway. To view the full press release, visit https://ibn.fm/8DJcl.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
This development matters because cardiovascular disease remains the leading cause of death globally, and early detection is critical for effective intervention. Cardio Diagnostics' approach leverages advanced technologies to offer personalized risk assessment, potentially shifting the paradigm from reactive treatment to proactive prevention. The company's expansion into India, a country with a high burden of cardiovascular disease, could significantly broaden access to these innovative tests. Additionally, progress in Medicare reimbursement is a key step toward making the tests widely available to the U.S. population, particularly older adults who are at higher risk.
The implications of this announcement are twofold. First, it signals that Cardio Diagnostics is advancing toward commercial viability, with reimbursement pathways being established. Second, the international expansion demonstrates scalability of the business model. For investors, the company's progress through the regulatory and reimbursement process could de-risk the investment thesis and pave the way for revenue generation. For patients and healthcare providers, the availability of precise, AI-driven diagnostics could improve outcomes by enabling earlier and more targeted interventions.
